These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29288176)

  • 1. Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study.
    Robinson Y; Olerud C; Willander J
    BMJ Open; 2017 Dec; 7(12):e016548. PubMed ID: 29288176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
    Glintborg B; Lindström U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordström D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jørgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Törmänen M; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson L
    Scand J Rheumatol; 2018 Nov; 47(6):465-474. PubMed ID: 30070923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis.
    Kim SH; Kim HR; Lee SH; Shin K; Kim HA; Min HK
    Sci Rep; 2021 Nov; 11(1):21555. PubMed ID: 34732807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset.
    Griffiths H; Smith T; Mack C; Leadbetter J; Butcher B; Acar M; Ciciriello S
    J Rheumatol; 2022 Feb; 49(2):150-156. PubMed ID: 34334362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical treatment improves survival of elderly with axis fracture-a national population-based multiregistry cohort study.
    Robinson AL; Olerud C; Robinson Y
    Spine J; 2018 Oct; 18(10):1853-1860. PubMed ID: 29649609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study.
    Abtahi S; Cordtz R; Dreyer L; Driessen JHM; Boonen A; Burden AM
    Am J Med; 2022 Jul; 135(7):879-888.e3. PubMed ID: 35134369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex.
    Law L; Beckman Rehnman J; Deminger A; Klingberg E; Jacobsson LTH; Forsblad-d'Elia H
    Arthritis Res Ther; 2018 Dec; 20(1):284. PubMed ID: 30587228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs.
    Keskin Y; Nas K; Kiliç E; Sargin B; Acer Kasman S; Alkan H; Şahin N; Cengiz G; Cuzdan N; Albayrak Gezer İ; Keskin D; Mülkoğlu C; Resorlu H; Ataman Ş; Bal A; Duruoz MT; Küçükakkas O; Yurdakul OV; Alkan Melikoğlu M; Aydin Y; Ayhan FF; Bodur H; Çaliş M; Çapkin E; Devrimsel G; Gök K; Hizmetli S; Kamanli A; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Arch Rheumatol; 2021 Mar; 36(1):1-9. PubMed ID: 34046563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome after traumatic spinal fractures in patients with ankylosing spinal disorders compared with control patients.
    Westerveld LA; van Bemmel JC; Dhert WJ; Oner FC; Verlaan JJ
    Spine J; 2014 May; 14(5):729-40. PubMed ID: 23992936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal cord injury after traumatic spine fracture in patients with ankylosing spinal disorders.
    Teunissen FR; Verbeek BM; Cha TD; Schwab JH
    J Neurosurg Spine; 2017 Dec; 27(6):709-716. PubMed ID: 28984512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Shin K
    BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
    Mease P; Walsh JA; Baraliakos X; Inman R; de Vlam K; Wei JC; Hunter T; Gallo G; Sandoval D; Zhao F; Dong Y; Bolce R; Marzo-Ortega H
    Rheumatol Ther; 2019 Sep; 6(3):435-450. PubMed ID: 31254223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabecular Bone Score (TBS) Predicts Fracture in Ankylosing Spondylitis: The Manitoba BMD Registry.
    Richards C; Hans D; Leslie WD
    J Clin Densitom; 2020; 23(4):543-548. PubMed ID: 32094033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
    J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Is the Difference in the Risk of Suicide Death Between Spine Fracture in Patients Older Than 65 Years and Matched Controls? A Large-database Study from South Korea.
    Jang SY; Cha Y; Kwak JH; Kim KJ; Kim HY; Choy WS
    Clin Orthop Relat Res; 2020 Nov; 478(11):2422-2430. PubMed ID: 33093384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankylosing Spondylitis and the Risk of Hip Fractures: a Matched Cohort Study.
    Tsur AM; David P; Watad A; Nissan D; Cohen AD; Amital H
    J Gen Intern Med; 2022 Oct; 37(13):3283-3288. PubMed ID: 35411534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.